Stockreport

Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

Cara Therapeutics, Inc.  (CARA) 
Last cara therapeutics, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.caratherapeutics.com/investor-relations
PDF STAMFORD, Conn., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new che [Read more]